---
document_datetime: 2023-09-21 21:57:07
document_pages: 19
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/xenical-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: xenical-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 12.1267382
conversion_datetime: 2025-12-17 15:10:02.328809
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Xenical

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0088              | B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                             | 10/05/2023                          |                                             | SmPC and PL                      |           |
| II/0086              | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported | 01/12/2022                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | by an ASMF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/2220/ 202202 | Periodic Safety Update EU Single assessment - orlistat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 29/09/2022 | n/a | PRAC Recommendation - maintenance |
| IA/0087            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/06/2022 | n/a |                                   |
| IA/0084/G          | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material) A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 17/11/2021 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0082/G   | This was an application for a group of variations.                                             | 07/08/2020   | n/a        |             |
|-------------|------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| IB/0081     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 14/04/2020   | 26/03/2021 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| IA/0080/G   | This was an application for a group of variations.   | 18/03/2020   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

|                    | Deletion of certificates (in case multiple certificates exist per material) B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                                                                                                                                                                                                                   |            |            |                 |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|-----------------------------------|
| PSUSA/2220/ 201902 | Periodic Safety Update EU Single assessment - orlistat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 03/10/2019 | n/a        |                 | PRAC Recommendation - maintenance |
| IAIN/0078          | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                       | 12/12/2018 | 14/11/2019 | Annex II and PL |                                   |
| IA/0077/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites | 17/11/2017 | n/a        |                 |                                   |

<div style=\"page-break-after: always\"></div>

|                    | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                         |            |            |                        |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| T/0076             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 05/04/2017 | 02/05/2017 | SmPC, Labelling and PL |                                   |
| IAIN/0075/G        | This was an application for a group of variations. B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in imprints, bossing or other markings B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 15/03/2017 | 02/05/2017 | SmPC, Annex II and PL  |                                   |
| PSUSA/2220/ 201602 | Periodic Safety Update EU Single assessment - orlistat                                                                                                                                                                                                                                                                                                                                                                                                                                | 02/09/2016 | n/a        |                        | PRAC Recommendation - maintenance |
| N/0074             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                      | 09/08/2016 | 02/05/2017 | Labelling              |                                   |
| IG/0667/G          | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer                                                                                                                                                                                                        | 08/04/2016 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|                    | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates exist per material)                                                                                                                                                                |            |            |             |                                                                                                                                           |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0071/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or | 10/12/2015 | n/a        |             |                                                                                                                                           |
| PSUSA/2220/ 201502 | Periodic Safety Update EU Single assessment - orlistat                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 24/09/2015 | 19/11/2015 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2220/201502. |
| IG/0573            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                            | 01/07/2015 | n/a        |             |                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IG/0497            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location   | 18/11/2014   | n/a        |                        |                                                         |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------------------------------------------|
| PSUSA/2220/ 201402 | Periodic Safety Update EU Single assessment - orlistat                                                                                                            | 11/09/2014   | n/a        |                        | PRAC Recommendation - maintenance                       |
| IB/0066            | B.II.f.1.d - Stability of FP - Change in storage conditions of the finished product or the diluted/reconstituted product                                          | 12/06/2014   | 26/08/2014 | SmPC, Labelling and PL |                                                         |
| IB/0065            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                    | 15/04/2014   | 26/08/2014 | SmPC, Labelling and PL |                                                         |
| PSUSA/2220/ 201308 | Periodic Safety Update EU Single assessment - orlistat                                                                                                            | 10/04/2014   | n/a        |                        | PRAC Recommendation - maintenance                       |
| IA/0063            | B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms                      | 21/08/2013   | 26/08/2014 | SmPC and PL            |                                                         |
| IG/0311            | B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer                  | 28/06/2013   | n/a        |                        |                                                         |
| IG/0228            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                    | 23/11/2012   | n/a        |                        |                                                         |
| A20/0059           | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on                                                                       | 19/07/2012   | 24/09/2012 |                        | Please refer to the assessment report : EMEA/H/C/154/A- |

<div style=\"page-break-after: always\"></div>

|          | 15 December 2011, the opinion of the CHMP on measures necessary to ensure the quality and the safe use of the above mentioned medicinal product further to the inspection findings at the manufacturing site Roche Carolina Inc. (RCI), Florence, in the United States of America (USA), to assess the impact thereof on the risk-benefit balance of Xenical and to give its opinion whether the marketing authorisation of this product should be maintained, varied, suspended or withdrawn.   |            |            |             | 20/0059                                                                                        |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------|
| IA/0060  | B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                       | 05/07/2012 | n/a        |             |                                                                                                |
| A20/0057 | Article 20 Review Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested the CHMP to assess the risk of serious hepatotoxicity and its impact on the risk-benefit balance of all orlistat- containing medicinal products and to give its opinion on measures necessary to ensure the safe and effective use of these products and on whether the marketing authorisations for these products should be maintained, varied, suspended or withdrawn.             | 16/02/2012 | 20/04/2012 | SmPC and PL | Please refer to the CHMP Assessment report for Xenical Art 20 procedure EMEA/H/C/154/A-20/0057 |

<div style=\"page-break-after: always\"></div>

| IG/0115/G   | This was an application for a group of variations. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate approved manufacturer                                                                                                                                                                         | 16/12/2011   | n/a   |             | from an already   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------|-------------------|
| IB/0056/G   | This was an application for a group of variations. B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                 | 07/07/2011   | n/a   |             |                   |
| IA/0055/G   | This was an application for a group of variations. B.III.1.b.2 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.II.a.1.a - Change or addition of imprints, bossing or other markings including replacement, or addition of inks used for product marking - Changes in | 02/05/2011   | n/a   | SmPC and PL |                   |

<div style=\"page-break-after: always\"></div>

|         | imprints, bossing or other markings B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                            |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0054 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                         | 31/03/2010 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| II/0053 | Update of sections 4.4 and 4.8 of the Summary of Product Characteristics (SPC) to include safety information on hyperoxaluria and oxalate nephropathy and hypothyroidism. Section 4.5 of the SPC was also updated to include information on interactions with anticonvulsivants and update the information on interaction with amodiarone. Section 2 of the Package Leaflet was amended accordingly. Update of Summary of Product Characteristics and Package Leaflet | 19/02/2009 | 25/03/2009 | SmPC and PL | During the review of the renewal, the CHMP requested additional information on renal disorders, drug interactions involving levothyroxine, amiodarone and anticonvulsivants. Following the review of this additional information, the CHMP concluded that an update of the Product Information should be made in sections 4.4, 4.5 and 4.8 of the SPC. This variation application was submitted further to this request of the CHMP and the following information was added: - The use of orlistat may be associated with hyperoxaluria and oxalate nephropathy in patients with underlying chronic kidney disease and/or volume depletion; - Rare occurrence of hypothyroidism and/or reduced control of hypothyroidism may occur. The mechanism, although not proven, may involve a decreased absorption of iodine salts and/or levothyroxine; - Antiepileptics patient: Orlistat may unbalance |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                        | anticonvulsivant treatment by decreasing the absorption of antiepileptic drugs, leading to convulsions. Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic drugs e.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded. Therefore, these patients should be monitored for possible changes in the frequency and/or severity of convulsions. - Oxalate nephropathy as a postmarketing adverse event. Special warnings and precautions for use related to the concomitant use with amodiarone was also updated to reflect that the clinical relevance of the slight decrease in plasma levels of amiodarone, when given as a single dose, remains unknown but may become clinically relevant in some cases.   |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0052 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 09/12/2008 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| R/0050  | Renewal of the marketing authorisation.                                                          | 24/04/2008 | 17/06/2008 | SmPC, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Xenical continues to be favourable. Pancreatitis has been included as an adverse reaction in section 4.8 of the SPC and section 4 of the Package Leaflet.                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0049 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 19/12/2007 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IA/0047 | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing | 05/11/2007 | n/a        | Annex II and PL        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| II/0045   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                                                                                                  | 20/09/2007   | 27/09/2007   |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0043    | The Marketing Authorisation Holder (MAH) applied for the inclusion of the Romanian and Bulgarian local representatives in the Package Leaflet. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 04/05/2007   | n/a          | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0044   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                            | 19/03/2007   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0042   | IA_09_Deletion of manufacturing site                                                                                                                                                                                                            | 26/10/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0041   | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer                                                                                                                                                             | 01/06/2006   | n/a          |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0039   | Update of Summary of Product Characteristics (SPC) to include safety information regarding rectal bleeding and unintended pregnancy. Update of Summary of Product Characteristics, Labelling and Package Leaflet                                | 27/04/2006   | 31/05/2006   | SmPC, Annex II, Labelling and PL | Following cases of rectal haemorrhage/blood in stool and unintended pregnancy associated with Xenical, the CHMP performed a reassessment of the available data and requested the MAH to submit this type II variation to update the product information for Xenical in order to include this safety information. With regards to rectal haemorrhage/blood in stool, the following information was included in the product information: Section 4.4 of the SPC (\"Cases of rectal bleeding have been reported with Xenical. Prescribers should investigate further in cases of severe and/or persistent symptoms\") and Section 4.8 of the SPC (\"Rarely |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                |            |            |                        | cases of rectal bleeding, generally of mild intensity have been reported\"). The package leaflet was amended accordingly. With regards to unintended pregnancy, the following information was included in the product information: Section 4.4 of the SPC (The use of an additional contraceptive method is recommended to prevent possible failure of oral contraception that could occur in case of severe diarrhoea (see Section 4.5)) and section 4.5 of the SPC (The absence of an interaction between oral contraceptives and orlistat has been demonstrated in specific drug-drug interaction studies. However, orlistat may indirectly reduce the availability of oral contraceptives and lead to unexpected pregnancies in some individual cases. An additional contraceptive method is recommended in case of severe diarrhoea (see Section 4.4)). The package leaflet was amended accordingly.   |
|---------|------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0040 | IA_39_Change/addition of imprints, bossing or other markings                                   | 16/03/2006 | n/a        | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0038 | IA_01_Change in the name and/or address of the marketing authorisation holder                  | 02/02/2006 | n/a        | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IA/0037 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer            | 22/07/2005 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| II/0034 | Update of section 5.1 of the SPC with data from a clinical trial in obese adolescent patients. | 21/04/2005 | 10/06/2005 | SmPC, Labelling and PL | The section 5.1 of the SPC was updated with information from a multi-centre, parallel-group, double-blind, placebo- controlled study in 539 obese adolescent patients,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | Update of Summary of Product Characteristics, Labelling and Package Leaflet                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |             | randomised to receive either 120 mg orlistat (n=357) or placebo (n=182) three times daily as an adjunct to a hypocaloric diet and exercise for 52 weeks with a primary endpoint of change in body mass index (BMI) from baseline to the end of the study. The results were significantly superior in the orlistat group (difference in BMI of 0.86 kg/m2 in favour of orlistat). 9.5 %of the orlistat treated patients versus 3.3 %of the placebo treated patients lost = 10 %of body weight after 1 year with a mean difference of 2.6 kg between the two groups. The difference was driven by the outcome in the group of patients with = 5 %weight loss after 12 weeks of treatment with orlistat representing 19 %of the initial population. The side effects were generally similar to those observed in adults. However, there was an unexplained increase in the incidence of bone fractures (6 %versus 2.8 %in the orlistat and placebo groups, respectively).   |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0036  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                       | 04/01/2005 | n/a        | Labelling   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| II/0031 | Update of sections 4.1 and 5.1 of the SPC removing the requirement that treatment with orlistat should only be started if diet alone has previously produced a weight loss of at least 2.5 kg over a period of 4 consecutive weeks, with the corresponding change to section 2 of the PL. In addition, the section 4.5 of the SPC was re-organised and the wording on the interaction with cyclosporine strengthened. Update of Summary of Product Characteristics and Package Leaflet | 29/07/2004 | 15/09/2004 | SmPC and PL | The section 4.1 of the SPC was updated to delete the pre- treatment 2.5 kg weight loss criterion while maintaining the second level of restriction, i.e. the >5% weight loss criterion at 12 weeks in the indication labelling.Clarification was provided in section 4.5 of the SPC on the recommendation for monitoring during concomittant use of cyclosporine with orlistat. Guidance was also provided on the lack of specific interactions observed in drug-drug interaction studies. The section 5.1 was updated to give more information on the results of the available analyses of the comparative                                                                                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                     |            |            |             | (orlistat vs. placebo) long term response in patients either able or unable to loose at least 5 %of the body weight at 12 weeks.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035 | IA_09_Deletion of manufacturing site                                                                                                                                                                | 07/09/2004 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0033 | IA_09_Deletion of manufacturing site                                                                                                                                                                | 06/08/2004 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| N/0032  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                    | 14/06/2004 | n/a        | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0029 | Update of sections 4.4, 4.5, 4.8 and 5.1 of the SPC and corresponding sections of the PL following completion of a clinical trial. Update of Summary of Product Characteristics and Package Leaflet | 21/01/2004 | 02/03/2004 | SmPC and PL | The SPC was updated with clinical data following the completion of a double-blind, placebo-controlled, randomised clinical trial (XENDOS study) Over 4 years, orlistat associated with diet significantly decreased body weight and BMI when compared to placebo. Consequently, the effect of orlistat with respect to the currently approved indication was adequately demonstrated over a long-time period. Data from the 4-year clinical trial showed 41% of the orlistat treated patients versus 21% of placebo treated patients lost 3 10% of body weight after 1 year with a mean difference of 4.4 kg between the two groups. After 4 years of treatment 21% of the orlistat treated patients compared to 10% of the placebo treated patients had lost 310% of body weight, with a mean difference of 2.7 kg.Data from the 4-year clinical trial also suggested that weight loss achieved with orlistat delayed the development of type 2 diabetes during the study (cumulative diabetes cases incidences: 3.4% in the orlistat group compared to 5.4% in the placebo-treated group). The great majority of diabetes cases came from the subgroup of patients with impaired glucose tolerance at baseline, which represented |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                     |            |            |                                  | 21% of the randomised patients. It is not known whether these findings translate into long-term clinical benefits.   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------|
| IB/0030 | IB_14_b_Change in manuf. of active substance without Ph. Eur. certificate - new manufacturer                                                                        | 27/11/2003 | n/a        |                                  |                                                                                                                      |
| R/0027  | Renewal of the marketing authorisation.                                                                                                                             | 26/06/2003 | 08/10/2003 | SmPC, Annex II, Labelling and PL |                                                                                                                      |
| II/0028 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                    | 26/06/2003 | 08/10/2003 | SmPC and PL                      |                                                                                                                      |
| II/0026 | Change(s) to shelf-life or storage conditions                                                                                                                       | 22/05/2003 | 27/05/2003 |                                  |                                                                                                                      |
| II/0025 | Change(s) to the manufacturing process for the finished product                                                                                                     | 25/04/2003 | 02/05/2003 |                                  |                                                                                                                      |
| II/0024 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                    | 21/11/2002 | 04/03/2003 | SmPC and PL                      |                                                                                                                      |
| II/0019 | Update of Summary of Product Characteristics and Package Leaflet                                                                                                    | 21/03/2002 | 20/06/2002 | SmPC and PL                      |                                                                                                                      |
| I/0023  | 12_Minor change of manufacturing process of the active substance 24a_Change in test procedure for starting material/intermediate used in manuf. of active substance | 11/01/2002 | 23/01/2002 |                                  |                                                                                                                      |
| I/0022  | 12_Minor change of manufacturing process of the active substance                                                                                                    | 11/01/2002 | 23/01/2002 |                                  |                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| I/0021   | 12_Minor change of manufacturing process of the active substance                                 | 11/01/2002   | 23/01/2002   |                 |
|----------|--------------------------------------------------------------------------------------------------|--------------|--------------|-----------------|
| II/0018  | Update of Summary of Product Characteristics                                                     | 27/06/2001   | 31/10/2001   | SmPC            |
| N/0020   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 09/07/2001   | 06/08/2001   | PL              |
| I/0017   | 15a_Change in IPCs applied during the manufacture of the product                                 | 27/06/2001   | 04/07/2001   |                 |
| I/0016   | 16_Change in the batch size of finished product                                                  | 27/06/2001   | 04/07/2001   |                 |
| I/0015   | 01_Change following modification(s) of the manufacturing authorisation(s)                        | 27/06/2001   | n/a          | Annex II and PL |
| II/0013  | Update of Summary of Product Characteristics                                                     | 25/01/2001   | 03/05/2001   | SmPC            |
| II/0012  | Update of Summary of Product Characteristics and Package Leaflet                                 | 25/01/2001   | 03/05/2001   | SmPC and PL     |
| II/0011  | Update of Summary of Product Characteristics and Package Leaflet                                 | 19/01/2000   | 11/05/2000   | SmPC and PL     |
| II/0010  | Update of Summary of Product Characteristics and Package Leaflet                                 | 29/07/1999   | 08/12/1999   | SmPC and PL     |
| I/0009   | 12_Minor change of manufacturing process of the active substance                                 | 19/05/1999   | 25/05/1999   |                 |

<div style=\"page-break-after: always\"></div>

| I/0007   | 12a_Change in specification of starting material/intermediate used in manuf. of the active substance                                                              | 13/05/1999   | 25/05/1999   |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|
| I/0005   | 24_Change in test procedure of active substance                                                                                                                   | 13/05/1999   | 25/05/1999   |
| I/0008   | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process                                                                    | 16/04/1999   | 18/05/1999   |
| II/0002  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Update of Summary of Product Characteristics and Package Leaflet | 27/01/1999   | 11/05/1999   |
| I/0006   | 15a_Change in IPCs applied during the manufacture of the product                                                                                                  | 31/03/1999   | n/a          |
| I/0004   | 11_Change in or addition of manufacturer(s) of active substance                                                                                                   | 26/02/1999   | 05/03/1999   |
| N/0001   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                  | 03/03/1999   | 11/05/1999   |
| I/0003   | 01_Change following modification(s) of the manufacturing authorisation(s)                                                                                         | 13/01/1999   | n/a          |